| Title: |
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials. |
| Authors: |
Sfairopoulos, Dimitrios; Liu, Tong; Zhang, Nan; Tse, Gary; Bazoukis, George; Letsas, Konstantinos; Goudis, Christos; Milionis, Haralampos; Vrettos, Apostolos; Korantzopoulos, P. |
| Publisher Information: |
Springer |
| Publication Year: |
2022 |
| Collection: |
Canterbury Christ Church University: CReaTE (Canterbury Research and Theses Environment) |
| Subject Terms: |
SGLT2 inhibitors; Atrial flutter; Atrial fibrillation; Heart failure |
| Description: |
Atrial fibrillation (AF) and atrial flutter (AFL) are associated with adverse outcomes in patients with heart failure and reduced ejection fraction (HFrEF). We investigated the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the incidence of AF and/or AFL in HFrEF patients. PubMed and ClinicalTrials.gov were systematically searched until March 2022 for randomized controlled trials (RCTs) that enrolled patients with HFrEF. A total of six RCTs with 9467 patients were included (N = 4731 in the SGLT2i arms; N = 4736 in the placebo arms). Compared to placebo, SGLT2i treatment was associated with a significant reduction in the risk of AF [relative risk (RR) 0.62, 95% confidence interval CI 0.44-0.86; P = 0.005] and AF/AFL (RR 0.64, 95% CI 0.47-0.87; P = 0.004). Subgroup analysis showed that empagliflozin use resulted in a significant reduction in the risk of AF (RR 0.55, 95% CI 0.34-0.89; P = 0.01) and AF/AFL (RR 0.50, 95% CI 0.32-0.77; P = 0.002). By contrast, dapagliflozin use was not associated with a significant reduction in the risk of AF (RR 0.69, 95% CI 0.43-1.11; P = 0.12) or AF/AFL (RR 0.82, 95% CI 0.53-1.27; P = 0.38). Additionally, a "shorter" duration (< 1.5 years) of treatment with SGLT2i remained associated with a reduction in the risk of AF (< 1.5 years; RR 0.58, 95% CI 0.36-0.91; P = 0.02) and AF/AFL (< 1.5 years; RR 0.52, 95% CI 0.34-0.80; P = 0.003). In conclusion, SGLT2i therapy was associated with a significant reduction in the risk of AF and AF/AFL in patients with HFrEF. These results reinforce the value of using SGLT2i in this setting. [Abstract copyright: © 2022. The Author(s).] |
| Document Type: |
article in journal/newspaper |
| Language: |
unknown |
| Relation: |
https://repository.canterbury.ac.uk/download/9adcfccd91b0c24af0a48e6fe1952b7096a96541821001365fc29ec01bd966c8/1842107/s10741-022-10281-3.pdf; https://doi.org/10.1007/s10741-022-10281-3 |
| Availability: |
https://repository.canterbury.ac.uk/item/930yq/association-between-sodium-glucose-cotransporter-2-inhibitors-and-incident-atrial-fibrillation-atrial-flutter-in-heart-failure-patients-with-reduced-ejection-fraction-a-meta-analysis-of-randomized |
| Rights: |
CC BY 4.0 |
| Accession Number: |
edsbas.C6B61FE5 |
| Database: |
BASE |